Third-Line Treatment for KRAS Wild-Type mCRC
For patients with metastatic colorectal cancer (mCRC) who are KRAS wild-type, third-line treatment options have evolved beyond standard chemotherapy. Recent clinical advancements emphasize precision medicine, utilizing targeted therapies such as ... Read More